XML 75 R65.htm IDEA: XBRL DOCUMENT
v3.23.3

Commitments and contingencies - Narrative (Details) - USD ($) $ in Thousands |  | 3 Months Ended | 9 Months Ended | 12 Months Ended |  |
--- | --- | --- | --- | --- | --- | ---
Apr. 29, 2020 | Jun. 30, 2016 | Sep. 30, 2023 | Dec. 31, 2022 | Sep. 30, 2022 | May 29, 2020
Other Commitments |  |  |  |  |  |
Milestone payable |  |  | $ 2,500 |  | $ 50,000 |
Accrued royalties |  |  | 52,087 | $ 40,546 |  |
Wellcome Trust |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Development milestone payment obligations |  |  |  | 2,500 |  |
Milestone obligation payments made |  | $ 800 |  |  |  |
Censa |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Asset acquisition, development and regulatory milestones |  |  |  |  |  | $ 109,000
Censa | Maximum |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Asset acquisition, milestone, amount |  |  |  |  |  | 217,500
Asset acquisition, net sales milestone |  |  |  |  |  | $ 160,000
Former Censa Securityholders |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Development milestone obligation payments made |  |  | 30,000 |  |  |
Development milestone obligation cash payments made |  |  | $ 400 |  |  |
Shares issued for milestone payment |  |  | 657,462 |  |  |
SMA License Agreement | SMA Foundation |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Royalty expense |  |  | $ 40,300 |  |  |
Royalty payments |  |  | 35,300 |  |  |
Accrued royalties |  |  | 5,000 |  |  |
SMA License Agreement | SMA Foundation | Maximum |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Potential royalty payments due on net product sales |  |  | 52,500 |  |  |
Agilis |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay | $ 40,000 |  | 40,000 |  |  |
Potential developmental and regulatory milestones |  |  | 31,100 |  |  |
Potential sales milestones |  |  | 50,000 |  |  |
Milestone obligation payments made |  |  |  | $ 50,000 |  |
Development milestone obligation payments made |  |  | $ 2,400 |  |  |
Agilis | Minimum |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Product sales (as a percent) |  |  | 2.00% |  |  |
Agilis | Maximum |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  | $ 60,000 |  |  |
Priority review voucher amount |  |  | 535,000 |  |  |
Potential sales milestones |  |  | $ 150,000 |  |  |
Product sales (as a percent) |  |  | 6.00% |  |  |
Development milestone payment obligations, net of cancellation and forfeiture |  |  | $ 20,000 |  |  |
Contingent liability, milestone, potential achievements, priority review voucher amount, net of cancellation and forfeiture |  |  | 361,000 |  |  |
Agilis | Rights Exchange Agreement |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Contingent liability cancellation and forfeiture of potential milestone payments | 174,000 |  |  |  |  |
Development milestone payment obligations, cancellation and forfeiture | 37,600 |  |  |  |  |
Contingent liability, cancellation and forfeiture | $ 211,600 |  |  |  |  |
BioElectron | Maximum |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  | 200,000 |  |  |
Marathon | Agilis Merger Agreement |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Milestone obligation payments made |  |  | 50,000 |  |  |
Net product revenue | Wellcome Trust | Maximum |  |  |  |  |  |
Other Commitments |  |  |  |  |  |
Development milestone payments which the entity is obligated to pay |  |  | $ 14,500 |  |  |

X
- Definition Asset Acquisition, Development And Regulatory Milestones + References No definition available. + Details
Name: | ptct_AssetAcquisitionDevelopmentAndRegulatoryMilestones
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Milestone, Amount + References No definition available. + Details
Name: | ptct_AssetAcquisitionMilestoneAmount
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Asset Acquisition, Net Sales Milestone + References No definition available. + Details
Name: | ptct_AssetAcquisitionNetSalesMilestone
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent Liability, Cancellation and Forfeiture + References No definition available. + Details
Name: | ptct_ContingentLiabilityCancellationAndForfeiture
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Liability cancellation and forfeiture, Milestone, Potential Achievements, Priority Review Voucher Amount + References No definition available. + Details
Name: | ptct_ContingentLiabilityCancellationAndForfeitureMilestonePotentialAchievementsPriorityReviewVoucherAmount
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of potential payments which may be due for developmental and regulatory milestones if achieved. + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsDevelopmentalAndRegulatoryMilestones
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent Liability, Milestone, Potential Achievements, Net Sales Milestone And Regulatory Approval + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsNetSalesMilestone
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmount
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Liability, Milestone, Potential Achievements, Priority Review Voucher Amount, Net of Cancellation and Forfeiture + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsPriorityReviewVoucherAmountNetofCancellationandForfeiture
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Contingent Liability, Milestone, Potential Achievements, Product Sales Percentage + References No definition available. + Details
Name: | ptct_ContingentLiabilityMilestonePotentialAchievementsProductSalesPercentage
Namespace Prefix: | ptct_
Data Type: | dtr-types:percentItemType
Balance Type: | na
Period Type: | instant

X
- Definition Amount of development milestone obligation payments made during the period. + References No definition available. + Details
Name: | ptct_DevelopmentMilestoneObligationPaymentsMade
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Amount of development milestone obligation cash payments made during the period. + References No definition available. + Details
Name: | ptct_DevelopmentMilestoneObligationPaymentsMadeCash
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements. + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligations
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development Milestone Payment Obligations, Cancellation and Forfeiture + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligationsCancellationAndForfeiture
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition Represents the development milestones payments which the entity is obligated to pay under certain contractual agreements. + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligationsDueOnSecondAnniversaryYearOfMergerClosing
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Development Milestone Payment Obligations, net of cancellation and forfeiture + References No definition available. + Details
Name: | ptct_DevelopmentMilestonePaymentObligationsNetofCancellationandForfeiture
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Definition The amount of recorded milestone payments payable. + References No definition available. + Details
Name: | ptct_MilestonePayable
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Amount of cash outflow for milestone obligations paid. + References No definition available. + Details
Name: | ptct_PaymentOfMilestoneObligation
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition The amount of potential royalties due on worldwide net product sales per terms of the collaboration agreement. + References No definition available. + Details
Name: | ptct_PotentialRoyaltiesDueNetProductSales
Namespace Prefix: | ptct_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Number of shares issued during the period as a result of a milestone payable. + References No definition available. + Details
Name: | ptct_StockIssuedDuringPeriodSharesMilestonePayable
Namespace Prefix: | ptct_
Data Type: | xbrli:sharesItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://www.xbrl.org/2003/role/exampleRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section 45 -Paragraph 8 -Subparagraph (c) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483467/210-10-45-8 Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Topic 210 -SubTopic 10 -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02.20) -Publisher FASB -URI https://asc.fasb.org//1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccruedRoyaltiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- References No definition available. + Details
Name: | us-gaap_OtherCommitmentsAbstract
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition The amount of cash paid for royalties during the current period. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Name Accounting Standards Codification -Section 45 -Paragraph 25 -Subparagraph (g) -SubTopic 10 -Topic 230 -Publisher FASB -URI https://asc.fasb.org//1943274/2147482740/230-10-45-25 + Details
Name: | us-gaap_PaymentsForRoyalties
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Amount of expense related to royalty payments under a contractual arrangement such as payment for mineral and drilling rights and use of technology or intellectual property. + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 220 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 2 -Subparagraph (SX 210.5-03.3) -Publisher FASB -URI https://asc.fasb.org//1943274/2147483621/220-10-S99-2 + Details
Name: | us-gaap_RoyaltyExpense
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | debit
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_WellcomeTrustLimitedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_CensaMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_FormerCensaSecurityholdersMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_CollaborativeArrangementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=ptct_SmaFoundationMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_AgilisMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=ptct_RightsExchangeAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_BusinessAcquisitionAxis=ptct_BioElectronMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | dei_LegalEntityAxis=ptct_MarathonPharmaceuticalsLLCMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=us-gaap_NoncollaborativeArrangementTransactionsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_ProductOrServiceAxis=us-gaap_ProductMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |